Zentalis Pharmaceuticals (ZNTL) Income from Continuing Operations (2022 - 2025)
Historic Income from Continuing Operations for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$26.7 million.
- Zentalis Pharmaceuticals' Income from Continuing Operations rose 3353.5% to -$26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.3 million, marking a year-over-year increase of 1673.86%. This contributed to the annual value of -$165.9 million for FY2024, which is 3996.66% up from last year.
- Per Zentalis Pharmaceuticals' latest filing, its Income from Continuing Operations stood at -$26.7 million for Q3 2025, which was up 3353.5% from -$26.9 million recorded in Q2 2025.
- In the past 5 years, Zentalis Pharmaceuticals' Income from Continuing Operations registered a high of $10.0 million during Q1 2024, and its lowest value of -$98.9 million during Q2 2023.
- Its 4-year average for Income from Continuing Operations is -$51.0 million, with a median of -$52.1 million in 2022.
- As far as peak fluctuations go, Zentalis Pharmaceuticals' Income from Continuing Operations soared by 11647.2% in 2024, and later crashed by 58086.65% in 2025.
- Over the past 4 years, Zentalis Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$48.2 million in 2022, then decreased by 26.53% to -$60.9 million in 2023, then rose by 22.1% to -$47.5 million in 2024, then soared by 43.78% to -$26.7 million in 2025.
- Its Income from Continuing Operations stands at -$26.7 million for Q3 2025, versus -$26.9 million for Q2 2025 and -$48.3 million for Q1 2025.